Article: Emerging pharmaceuticals: Mutant isocitrate dehydrogenase (mIDH) inhibitors

Related products

• 

  Article: INTRODUCTION

  €3.03 Add to cart
• 

  Article: Highlights in respiratory oncology

  €3.03 Add to cart
• 

  Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer

  €3.03 Add to cart
• 

  Article: Highlights in squamous cell carcinoma of the head and neck

  €3.03 Add to cart